Ventricular Tachycardia Mechanisms

Description

The purpose of this study is to understand why certain hearts have ventricular arrhythmias and help identify areas of the heart that cause arrhythmias. There is still a significant gap in understanding why ventricular arrhythmias occur. This study will examine the electrical properties of the heart tissue to understand how these arrhythmias occur, and hopefully identify areas that might lead to ventricular arrhythmias. The hope is that studying this might be able to improve outcomes during ventricular tachycardia (VT) ablations.

Conditions

Ventricular Tachycardia

Study Overview

Study Details

Study overview

The purpose of this study is to understand why certain hearts have ventricular arrhythmias and help identify areas of the heart that cause arrhythmias. There is still a significant gap in understanding why ventricular arrhythmias occur. This study will examine the electrical properties of the heart tissue to understand how these arrhythmias occur, and hopefully identify areas that might lead to ventricular arrhythmias. The hope is that studying this might be able to improve outcomes during ventricular tachycardia (VT) ablations.

Ventricular Tachycardia Substrate Mechanisms Revealed by Local Repolarization and Conduction Parameters

Ventricular Tachycardia Mechanisms

Condition
Ventricular Tachycardia
Intervention / Treatment

-

Contacts and Locations

Atlanta

Emory University Hospital Midtown, Atlanta, Georgia, United States, 30308

Atlanta

Emory Clinic, Atlanta, Georgia, United States, 30322

Atlanta

Emory University Hospital, Atlanta, Georgia, United States, 30322

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of ischemic cardiomyopathy
  • * Single or dual chamber implantable cardioverter-defibrillator (ICD)
  • * Non-Ischemic cardiomyopathy
  • * Contraindication to catheter ablation
  • * Severe peripheral arterial disease or medical condition that prohibit arterial access
  • * Ventricular tachycardia (VT) or sudden cardiac arrest (SCA) within 30 days of acute coronary syndrome or within 90 days of coronary revascularization

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Emory University,

Neal Bhatia, MD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

2025-03